Foamix, Telormedix deal
The companies received €947,617 ($1.2 million) in funding from the Eureka-Eurostars program to coordinate a two-year research project named TOSCA aimed at developing new topical treatments for skin cancer based on a foam formulation of Telormedix's TMX-202. The companies said the project is focused on developing a safe and effective topical treatment for skin cancer, actinic keratosis and genital warts by combining the target-specific binding properties of TMX-202 with a foam formulation to optimize skin penetration, drug delivery and patient compliance. TOSCA also includes academic partners Charite - Universitatsmedizin Berlin and the German Cancer Research Center. TMX-202, a small molecule toll-like receptor 7 (TLR7) agonist, is in preclinical testing for the topical treatment of skin and bladder cancers. Foamix develops topical foam delivery systems. ...